LGVN News and Press, Longeveron Inc. From 03/10/23

2023-03-10 18:40:04 ET Longeveron Inc. (LGVN) Q4 2022 Results Conference Call March 10, 2023 08:30 AM ET Company Participants James Clavijo - CFO Wa’el Hashad - CEO Dr. Chris Min - Chief Medical Officer Conference Call Participants Michael Okun...

2023-03-10 08:03:06 ET Longeveron press release ( NASDAQ: LGVN ): Q4 GAAP EPS of -$0.21 misses by $0.01 . Cash and short-term investments was $19.6 million compared to $35.0 million as of December 31, 2022 and 2021, respectively. The decrease in cash period over period...

MIAMI, March 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its fourth quarter and full year 2022 financial res...

Clinical stage biotechnology company, Longeveron ( NASDAQ: LGVN ) appoints of seasoned global pharmaceutical leader Wa’el Hashad as CEO, effective March 1, 2023. Following Mr. Hashad joining Longeveron, current interim CEO Chris Min, M.D., Ph.D., will co...

Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over 35 years of experience with focus on drug approval and commercialization, mergers and acquisitions, and business development MIAM...

-- Full results published in European Heart Journal Open -- -- Study met primary safety endpoint -- -- All patients alive, transplant-free, and maintained expected rate of growth one year after treatment -- -- Data supports ongoing clinical development of Lomecel-B...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In November 2021, I made an outlandish effort to pick 5 cheap stocks that could double within a month . Few companies rise 100%, and even fewer can do it in the time it takes to properly pickle a cucumber . Nevertheless, my...

– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "...

– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Last Wednesday, we finally got the announcement: Elon Musk had sold another $3.6 billion of Tesla (NASDAQ: TSLA ) stock earlier in the week. (SEC filings tend to lag several days behind transactions). Such a sale had ...